119 related articles for article (PubMed ID: 15820440)
1. Different antioxidative potencies of dihydropyridine calcium channel modulators in various models.
Berkels R; Breitenbach T; Bartels H; Taubert D; Rosenkranz A; Klaus W; Roesen R
Vascul Pharmacol; 2005 Mar; 42(4):145-52. PubMed ID: 15820440
[TBL] [Abstract][Full Text] [Related]
2. Amlodipine increases endothelial nitric oxide by dual mechanisms.
Berkels R; Taubert D; Bartels H; Breitenbach T; Klaus W; Roesen R
Pharmacology; 2004 Jan; 70(1):39-45. PubMed ID: 14646355
[TBL] [Abstract][Full Text] [Related]
3. Unique atheroprotective property of azelnidipine, a dihydropyridine-based calcium antagonist.
Nakamura K; Yamagishi S; Inoue H
Med Hypotheses; 2005; 65(1):155-7. PubMed ID: 15893134
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the interaction between lacidipine and BAY K 8644 in two isolated rabbit arteries.
Giacometti A; Quartaroli M; Gaviraghi G; Micheli D; Trist D
J Pharmacol Exp Ther; 1992 Dec; 263(3):1241-7. PubMed ID: 1281877
[TBL] [Abstract][Full Text] [Related]
5. Nifedipine increases endothelial nitric oxide bioavailability by antioxidative mechanisms.
Berkels R; Egink G; Marsen TA; Bartels H; Roesen R; Klaus W
Hypertension; 2001 Feb; 37(2):240-5. PubMed ID: 11230278
[TBL] [Abstract][Full Text] [Related]
6. Quantification of the calcium antagonism of lacidipine by kinetic analysis.
Giacometti A; Micheli D; Gaviraghi G; Trist DG
J Pharmacol Exp Ther; 1994 Apr; 269(1):424-9. PubMed ID: 8169848
[TBL] [Abstract][Full Text] [Related]
7. Antioxidant activity of different dihydropyridines.
Cominacini L; Fratta Pasini A; Garbin U; Pastorino AM; Davoli A; Nava C; Campagnola M; Rossato P; Lo Cascio V
Biochem Biophys Res Commun; 2003 Mar; 302(4):679-84. PubMed ID: 12646222
[TBL] [Abstract][Full Text] [Related]
8. Pharmacology of the dihydropyridine calcium antagonists: relationship between lipophilicity and pharmacodynamic responses.
van Zwieten PA; Pfaffendorf M
J Hypertens Suppl; 1993 Dec; 11(6):S3-8. PubMed ID: 8169379
[TBL] [Abstract][Full Text] [Related]
9. Dual effect of dihydropyridines on 45Ca uptake induced by the K+ -channel blocker, 4-aminopyridin on mast cells.
Eleno N; Botana L; Espinosa J
J Cell Physiol; 1988 Nov; 137(2):378-83. PubMed ID: 2461378
[TBL] [Abstract][Full Text] [Related]
10. Scavenging properties of metronidazole on free oxygen radicals in a skin lipid model system.
Narayanan S; Hünerbein A; Getie M; Jäckel A; Neubert RH
J Pharm Pharmacol; 2007 Aug; 59(8):1125-30. PubMed ID: 17725855
[TBL] [Abstract][Full Text] [Related]
11. Competitive and cooperative effects of Bay K8644 on the L-type calcium channel current inhibition by calcium channel antagonists.
Zahradníková A; Minarovic I; Zahradník I
J Pharmacol Exp Ther; 2007 Aug; 322(2):638-45. PubMed ID: 17475903
[TBL] [Abstract][Full Text] [Related]
12. Nisoldipine increases the bioavailability of endothelial NO.
Berkels R; Roesen R; Bartels H; Purol-Schnabel S; Kirmiziguel I; Farmer H; Born GV; Klaus W
Naunyn Schmiedebergs Arch Pharmacol; 2001 Aug; 364(2):110-6. PubMed ID: 11534850
[TBL] [Abstract][Full Text] [Related]
13. Bay w 9798, a dihydropyridine structurally related to nifedipine with no calcium channel-blocking properties, inhibits tumour necrosis factor-alpha-induced vascular cell adhesion molecule-1 expression in endothelial cells by suppressing reactive oxygen species generation.
Matsui T; Yamagishi S; Nakamura K; Inoue H
J Int Med Res; 2007; 35(6):886-91. PubMed ID: 18084847
[TBL] [Abstract][Full Text] [Related]
14. Benidipine, an anti-hypertensive drug, inhibits reactive oxygen species production in polymorphonuclear leukocytes and oxidative stress in salt-loaded stroke-prone spontaneously hypertensive rats.
Matsubara M; Akizuki O; Ikeda J; Saeki K; Yao K; Sasaki K
Eur J Pharmacol; 2008 Feb; 580(1-2):201-13. PubMed ID: 18048030
[TBL] [Abstract][Full Text] [Related]
15. 1,4-Dihydropyridine calcium channel blockers inhibit plasma and LDL oxidation and formation of oxidation-specific epitopes in the arterial wall and prolong survival in stroke-prone spontaneously hypertensive rats.
Napoli C; Salomone S; Godfraind T; Palinski W; Capuzzi DM; Palumbo G; D'Armiento FP; Donzelli R; de Nigris F; Capizzi RL; Mancini M; Gonnella JS; Bianchi A
Stroke; 1999 Sep; 30(9):1907-15. PubMed ID: 10471444
[TBL] [Abstract][Full Text] [Related]
16. The pharmacological properties of lipophilic calcium antagonists.
van Zwieten PA
Blood Press Suppl; 1998; 2():5-9. PubMed ID: 9850436
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of 1,4-dihydropyridine calcium channel modulators having a diazen-1-ium-1,2-diolate nitric oxide donor moiety for the potential treatment of congestive heart failure.
Velázquez C; Knaus EE
Bioorg Med Chem; 2004 Jul; 12(14):3831-40. PubMed ID: 15210150
[TBL] [Abstract][Full Text] [Related]
18. Action of mibefradil and lacidipine on the isolated human anterior tibial artery.
Martinuc J; Drevensek G; Budihna MV
Pflugers Arch; 2000; 440(5 Suppl):R147-8. PubMed ID: 11005648
[TBL] [Abstract][Full Text] [Related]
19. Azelnidipine, a dihydropyridine-based calcium antagonist, inhibits angiotensin II-induced oxidative stress generation and downregulation of pigment epithelium-derived factor mRNA levels in microvascular endothelial cells.
Matsui T; Yamagishi S; Nakamura K; Kikuchi S; Inoue H
Drugs Exp Clin Res; 2005; 31(5-6):215-9. PubMed ID: 16425978
[TBL] [Abstract][Full Text] [Related]
20. Blockade of T-type voltage-dependent Ca2+ channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R.
Akizuki O; Inayoshi A; Kitayama T; Yao K; Shirakura S; Sasaki K; Kusaka H; Matsubara M
Eur J Pharmacol; 2008 Apr; 584(2-3):424-34. PubMed ID: 18331727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
